Zentalis Pharmaceuticals

Zentalis Pharmaceuticals describes itself as developing a differentiated oral therapy targeting WEE1 kinase, a key regulator of cell-cycle progression. Its focus is azenosertib, an investigational drug that it states leads the WEE1 targeting field and is currently in registration-intended studies. The company states it is advancing the first oral, non-chemotherapy, biomarker-driven approach specifically for Cyclin E1 positive platinum-resistant ovarian cancer patients. Its leadership team is led by Chief Executive Officer and Director Julie Eastland.

Zentalis Pharmaceuticals is described in Wikidata as a company in San Diego, United States. Its official website states that it is developing a differentiated oral therapy that targets WEE1 kinase, a key regulator of cell-cycle progression, and that it is focused on azenosertib, an investigational drug. The company states that azenosertib leads the WEE1 targeting field and is currently in registration-intended studies, and that it is advancing the first oral, non-chemotherapy, biomarker-driven approach specifically for Cyclin E1 positive platinum-resistant ovarian cancer patients. Its leadership team is led by Chief Executive Officer and Director Julie Eastland.

Developing a differentiated oral therapy targeting WEE1 kinase, focused on azenosertib as an investigational targeted, oral therapy option.

• Azenosertib

  An investigational selective inhibitor of WEE1, described by Zentalis as an oral, non-chemotherapy, biomarker-driven approach initially for Cyclin E1 positive, platinum-resistant ovarian cancer (PROC).

1. 1Zentalis Pharmaceuticals | Advancing WEE1-Targeted Oncologyzentalis.com
2. 2Leadership | Zentalis Pharmaceuticals – Experienced Oncology Teamzentalis.com
3. 3Our Approach | Zentalis Pharmaceuticals – A New Approach to Ovarian Cancerzentalis.com
4. 4Zentalis Pharmaceuticals (United States)wikidata.org